What is Nyxoah?
Headquartered in Mont-Saint-Guibert, Belgium, Nyxoah is a specialized medical technology firm dedicated to the development and commercialization of innovative solutions for Obstructive Sleep Apnea (OSA). The company operates at the intersection of healthcare technology and respiratory medicine, focusing on addressing the significant global burden of sleep-disordered breathing. By leveraging advanced neurostimulation and digital health integration, Nyxoah aims to provide patients with effective, non-invasive alternatives to traditional therapies. Its market position is bolstered by a strong intellectual property portfolio and strategic partnerships with established industry giants, allowing it to navigate the complex regulatory and clinical pathways inherent in the medical device industry.
How much funding has Nyxoah raised?
Nyxoah has raised a total of $371.7M across 8 funding rounds:
Series A
$11M
Private Equity
$20M
Private Equity
$27.2M
Stock Offering
$99.6M
Share Placement
$15M
Share Placement
$27M
Stock/Share Issuance
$77M
Private Equity
$95M
Series A (2014): $11M, investors not publicly disclosed
Private Equity (2016): $20M led by Glide Healthcare and Novallia
Private Equity (2020): $27.2M supported by Resmed Inc
Stock Issuance/Offering (2020): $99.6M, investors not publicly disclosed
Share Placement (2023): $15M, investors not publicly disclosed
Share Placement (2024): $27M, investors not publicly disclosed
Stock/Share Issuance (2025): $77M led by Cochlear and ResMed
Private Equity (2026): $95M, investors not publicly disclosed
Key Investors in Nyxoah
Cochlear
Headquartered in New South Wales, Australia, Cochlear is a medical device company that designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant.
ResMed
ResMed is a global healthcare technology company that develops innovative medical devices, digital health solutions, and cloud-connected software to improve the diagnosis, treatment, and management of sleep disorders.
Gilde Healthcare
Gilde Healthcare is a specialized healthcare investment firm managing over 1.4 billion across three fund strategies, focusing on businesses that enable better care at lower costs.
What's next for Nyxoah?
With the successful completion of this major strategic investment, Nyxoah is well-positioned to scale its commercial operations and expand its market footprint. The company is expected to prioritize the clinical validation and global rollout of its OSA treatment platforms, leveraging the expertise of its strategic partners to optimize supply chain and distribution networks. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward enhancing patient outcomes through data-driven insights and expanding its therapeutic reach into new geographic markets. This capital infusion provides the necessary runway to sustain innovation and maintain a competitive edge in the rapidly evolving sleep health sector.
See full Nyxoah company page
